Veracyte Secures NY State Approval for Genomic Classifier Test for Lung Disease

Apr 23, 2019

|

NEW YORK (GenomeWeb) – Veracyte has received regulatory approval from the New York State Department of Health to offer its Envisia Genomic Classifier test to patients in the state immediately, the company said on Monday. The test uses RNA sequencing and machine learning to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILD) without surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

Cell Engineering 101

CRISPR 101

Gene Knockouts: How CRISPR Is Used to Inactivate Genes

Compatibility of liquid biopsy assays on multiple sequencing platforms

Jun

04

Featured Webinar

A CRISPR Study to Decipher the Role of Genetic Risk Variants in Glaucoma

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance.

Jun

06

Featured Webinar

Accelerating Crop Research with High-Quality Affordable Genome Assemblies

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.

Jun

11

Featured Webinar

The Promise of Liquid Biopsy in Lung Cancer Monitoring

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Menu